(R)-Etodolac

（R）-依托度酸

Report date: 2024/12/03 11:24:03
NME

Base Information

Drug Name(R)-Etodolac
Drug Alias NameRAK-593SDX-101CEP-18082SDX-308SDX-309 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonistsCatenin beta 1 inhibitorsNuclear factor NF-kappa-B complex inhibitors
TargetsPeroxisome proliferator-activated receptor γCatenin beta 1Nuclear factor NF-kappa-B complex
Therapy Area/IndicationsMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwedenPoland +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMyriad Genetics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSalmedix IncCephalon
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksWikipedia